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Abstract
Background: The cellular apoptosis susceptibility (CAS) protein is regarded as a proliferation-
associated protein that associates with tumour proliferation as it associates with microtubule and
functions in the mitotic spindle checkpoint. However, there is no any actual experimental study
showing CAS (or CSE1 and CSE1L) can increase the proliferation of cancer cells. Previous
pathological study has reported that CAS was strongly positive stained in all of the metastasis
melanoma that be examined. Thus, CAS may regulate the invasion and metastasis of cancers. CAS
is highly expressed in cancers; if CAS is associated with cancer proliferation, then increased CAS
expression should be able to increase the proliferation of cancer cells. We studied whether
increased CAS expression can increase cancer cell proliferation and whether CAS regulates the
invasion of cancer cells.
Methods: We enhanced or reduced CAS expression by transfecting CAS or anti-CAS expression
vectors into human MCF-7 breast cancer cells. The proliferations of cells were determined by
trypan blue exclusion assay and flow cytometry analysis. Invasion of cancer cells were determined
by matrigel-based invasion assay.
Results: Our studies showed that increased CAS expression was unable to enhance cancer cell
proliferation. Immunofluorescence showed CAS was distributed in cytoplasm areas near cell
membrane and cell protrusions. CAS was localized in cytoplasmic vesicle and immunogold
electronmicroscopy showed CAS was located in vesicle membrane. CAS overexpression enhanced
matrix metalloproteinase-2 (MMP-2) secretion and cancer cell invasion. Animal experiments
showed CAS reduction inhibited the metastasis of B16-F10 melanoma cells by 56% in C57BL/6
mice.
Conclusion: Our results indicate that CAS increases the invasion but not the proliferation of
cancer cells. Thus, CAS plus ECM-degradation proteinases may be used as the markers for
predicting the advance of tumour metastasis.
Published: 3 July 2008
Journal of Experimental & Clinical Cancer Research 2008, 27:15 doi:10.1186/1756-9966-27-
15
Received: 1 May 2008
Accepted: 3 July 2008
This article is available from: http://www.jeccr.com/content/27/1/15
© 2008 Liao et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2008, 27:15 http://www.jeccr.com/content/27/1/15Background
The cellular apoptosis susceptibility (CAS) protein is
highly expressed in various cancers including melanomas,
lymphomas, breast cancers, hepatomas, ovarian carcino-
mas, endometrial carcinomas, and colorectal cancers [1-
8]. Also, the expression of CAS is correlated positively
with high stage and high-grade cancers as well as worse
outcome of the cancer patients [1-8]. Thus, CAS may play
an important role in regulating cancer development and
progression.
CAS is the human homologue of the yeast chromosome
segregation gene, CSE1 [9]. CAS is associated with micro-
tubules and mitotic spindles, the cellular organelles for
cell cycle mitosis division; hence CAS is speculated to play
a role in cell proliferation and is regarded as a prolifera-
tion-associated protein [1,10]. Consequently, many path-
ological studies demonstrated that the expression of CAS
in tumors is related with tumor proliferation in cancer
development [2-5]; although there is no any actual exper-
imental study showing CAS can increase cancer prolifera-
tion. CAS is highly expressed in cancers; if CAS regulates
cancer proliferation during cancer development, then
increased CAS expression in cancer cells should be able to
increase the proliferation of cancer cells. Instead, our
recent study showed that increased CAS expression in
human HT-29 colorectal cancer cells inhibited but not
stimulated the proliferation of HT-29 cells [11].
Metastatic tumours secrete extracellular matrix (ECM)-
degradation proteinases to degrade ECM during invasion.
MMP-2 is an ECM-degradation proteinase that secreted
from invasive cancer cells and plays an important role in
tumor metastasis regulation [12,13]. Tumour cells with
strong secretion activities can enhance the secretion of
ECM-degradation proteinases and enhance tumour
metastasis [14,15]. Experiment showed that MMPs pro-
duction could be regulated at the level of secretion [16].
Thus, for increasing their invasion and metastasis ability,
metastatic tumour cells may develop strong secretory abil-
ity to enhance MMPs secretion.
CAS was identified in a study of an antisense DNA frag-
ment that is capable of causing cell resistance to apoptosis
induced by bacterial toxins and tumor necrosis factors
[17]. CAS also regulates apoptosis induced by cypermeth-
rin [18], interferon-γ [19], and chemotherapeutic drugs
including doxorubicin, 5-fluorouracil, tamoxifen, and cis-
platin [20]. Pathological studies showed that the expres-
sion of CAS was related positively with high stage and
high grade of cancers, as well as worse outcome of the
patients [1-8]. Notably, a pathological study reported that
CAS was strongly positive stained in all of the metastasis
melanoma that be examined (n = 23) [2]. Thus, CAS may
regulate the invasion and metastasis of cancers.
Tumor metastases are the main characteristics of high
grade cancers and are also the main causes of cancer-
related mortality. Our recent study also showed that CAS
transfection was unable to increase the proliferation of
HT-29 cancer cells. Thus, we speculate that CAS regulates
invasion and metastasis but not proliferation of cancers.
We report here that CAS enhances invasion and metastasis
but not proliferation of cancer cells.
Methods
Antibodies
Antibodies used in the experiment were mouse anti-CAS
monoclonal antibodies (clone 24) (BD Pharmingen
Transduction Laboratories, San Diego, CA, USA); rabbit
anti-MMP-2 polyclonal antibodies (H-76) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA); mouse anti-β-actin
monoclonal antibodies (Ab-5) (Neomarker, Westing-
house Drive, CA, USA); goat anti-mouse (or anti-rabbit)
IgG secondary antibodies coupled to Alexa Fluor 488 (or
Alexa Fluor 568) (Molecular Probes, Eugene, OR, USA);
goat anti-mouse IgG secondary antibodies coupled to
gold (Jackson ImmunoResearch, West Grove, PA, USA).
Vectors
We isolated total cellular RNA from HT-29 cells with the
Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse
transcription reaction was carried out using the 1st-strand
cDNA synthesis kit (Clontech Laboratories, Palo Alto, CA,
USA). The reverse transcription reaction mixture (20 μl)
containing 1 μg of DNase-treated total RNA, 20 pmol
oligo (dT)18 primer, 50 mM Tris-HCl pH 8.3, 75 mM KCl,
3 mM MgCl2, 0.5 mM each of dNTP, 1 unit RNase inhib-
itor, and 200 units/μg RNA of MMLV reverse transcriptase
was incubated at 42°C for 1 hour. The PCR reactions were
done in a 50-μl reaction mixture containing 5 μl of the
reverse transcription reaction mixture, 100 ng each of
primer, 0.3 mM Tris-HCl pH 8.0, 1.5 mM KCl, 1 μM
EDTA, 1% glycerol, 0.2 mM each of dNTP, and 1 μl of
50×Advantage 2 polymerase mix (Clontech). Primers
used to amplify CAS cDNA were 5'-TATAGCAAT-
GGAACTCAGCGATGC (sense) and 5'-AGTTTAAAG-
CAGTGTCACACTGGC (antisense). The DNA was
amplified in a GeneAmp PCR System 9700 (Perkin-Elmer,
Norwalk, CT. USA) for 35 cycles using the following
parameters: 94°C for 30 seconds, 65°C for 30 seconds,
and 72°C for 200 seconds with a final extension step at
72°C for 10 minutes. The amplified products were
resolved in 1% agarose gel with ethidium bromide. The
DNA was eluted and cloned into pGEM-T vector
(Promega Corporation, Madison, WI, USA), and was sub-
sequently cloned into the pcDNA3.1 eukaryotic expres-
sion vector (Invirogen) to obtain pcDNA-CAS vector. The
pcDNA-CAS vector was cut with Apa I and Hind III, and
the 516-bp CAS fragment (bp 1 to 516) was cloned into
the Apa I and Hind III sites of pcDNA3.1 vector in an anti-Page 2 of 12
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identities of the DNA sequences were determined by DNA
sequencing.
Cells and DNA transfections
MCF-7 breast cancer cells, 293 embryo kidney cells, and
B16-F10 mouse melanoma cells were from American
Type Culture Collection (Manassas, VA, USA). Cultures of
cells were as previously described [21]. Cells were trans-
fected with vectors using the Lipofectamine plus reagent
(Invitrogen). Transfected cells were selected with a high
concentration of G418 for 3 weeks. Multiple drug-resist-
ant colonies (> 100) were pooled together and amplified
in mass culture. The transfected cells were maintained in
media containing 200 μg/ml G418. For the experiments,
cells were cultured in media without G418 and the media
were refreshed every 4 days, as MCF-CAS cells are rela-
tively prone to apoptosis in long-time culture when not
supplemented with fresh media.
Immunoblotting
Cells were washed with PBS and harvested by scraping.
The harvested cells were washed with PBS and lysed in
RIPA buffer (25 mM Tris-HC1 [pH 7.2], 0.1% SDS, 0.1%
Triton X-100, 1% sodium deoxycholate, 150 mM NaCl, 1
mM EDTA, 1 mM sodium orthovanadate, 1 mM phenyl-
methylsulfonyl fluoride, 10 μg/ml aprotinin, and 5 μg/ml
leupeptin). The protein concentrations were determined
with a BCA protein assay kit (Pierce, Rockford, IL, USA).
Fifty micrograms of each protein sample was loaded onto
SDS-polyacrylamide gel. Proteins were transferred to
nitrocellulose membranes (Amersham Pharmacia, Buck-
inghamshire, UK). The membrane was blocked at 4°C for
overnight with blocking buffer (1% BSA, 50 mM Tris-HCl,
pH 7.6, 150 mM NaCl, 0.1% Tween-20). The blots were
incubated for 1 hour at room temperature (RT) with pri-
mary antibodies followed by incubated with secondary
antibodies conjugated to horseradish peroxidase for 1
hour. The levels of protein were detected by enhanced
chemiluminescence with an ECL Western blotting detec-
tion system (Amersham Pharmacia).
Cell proliferation assay
Equal numbers of cells (1 × 104 cells/dish) were seed on
100 mm culture dishes. The media were refreshed every
three days. The cell numbers were countered every 24
hours by trypan blue exclusion assays after cell seeding.
For each time point, three plates of cells were counted,
and each plate was only counted once.
Flow cytometry analysis
Cells were harvested by 0.1% trypsin-EDTA digestion,
washed with PBS containing 0.1% glucose, and fixed in
70% ethanol at 4°C for 16 hours. Cells was stained with
a propidium iodide (PI) staining solution containing 100
μg/ml PI, 100 μg/ml RNase A, and 0.1% glucose for 30
minutes. The PI fluorescence was measured with a BD
FACS Canto flow cytometer (BD Biosciences, Bedford,
MA, USA). A minimum of 10,000 cells in each treatment
was analyzed in the flow cytometry analysis.
The proportion of each cell phase was expressed as per-
centage of the total number of the living cells. The propor-
tion of sub-G1 of each treatment was expressed as
percentage of the total number of cells.
Immunofluorescence
Cells grown on coverslips (12 × 12 mm) were cytospun at
1000 rpm for 10 minutes. Cells were washed with PBS,
fixed with 4% paraformaldehyde, permeabilized with
0.1% Triton X-100 in 4% paraformaldehyde, and blocked
with PBS containing 0.1% BSA and 0.5% Tween-20. Cells
were incubated with primary antibodies, washed with
PBS, incubated with goat anti-mouse (or anti-rabbit) IgG
secondary antibodies coupled to Alexa Fluor 488 (or
568). Coverslips were examined with a Zeiss Axiovert 200
M inverted fluorescence microscope. Experiments were
carried out on duplicate coverslips of three independent
experiments and five random fields were imaged per cov-
erslip.
Immunogold electron microscopy
Cells were washed with PBS and fixed in a mixture of
0.5% glutaraldehyde and 2% paraformaldehyde in Hepes
buffer (pH 6.8) for 15 minutes and then in 2% parafor-
maldehyde in Hepes buffer (pH 6.8) at 4°C for 14 days.
Samples were dehydrated with 80% ethanol and infil-
trated with increasing concentrations of Lowicryl HM20
resin (Polysciences, Tokyo, Japan). Polymerization of
Lowicryl HM20 was performed by UV irradiation (wave-
length peak at 360 nm) for 24 hours. Ultrathin sections
were cut and then mounted on nickel grids coated with
2% Neoprene (Ohken, Tokyo, Japan). After being sunk in
100% ethanol for 3 minutes, samples were immersed in
0.01 M EDTA (pH 7.2) at 65°C for 24 hours. The samples
were washed with PBS three times (5 minutes/wash) and
blocked with PBS containing 1% BSA and 0.1% Tween-20
for 15 minutes. The samples were incubated with a mix-
tures of primary antibodies diluted in PBS (1:30) for 1
hour, washed with PBS three times (5 minutes/wash),
reacted with 12-nm gold-labeled secondary antibodies,
followed by washing with PBS three times (5 minutes/
wash). The samples were stained with uranyl acetate and
were examined on a Hitachi H-7000 transmission elec-
tron microscope.
MM-2 secretion analysis
Equal numbers of cells were seed on 100 mm culture
dishes. Serum contains high level of endogenous MM-2
and may interfere with the MM-2 secretion assay, thusPage 3 of 12
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media without serum supplement for 36 hours. The con-
ditioned media were harvested and the cell numbers were
determined. The cell number standardized conditioned
media were resolved in 10% SDS-PAGE and the levels of
MMP-2 in media were analyzed by immunoblotting with
anti-MMP-2 antibodies.
Matrigel-based invasion assay
Polyvinylpyrrolidone-free polycarbonate filters with 8-
μm pore size (Costar, Cambridge, MA, USA) were soaked
in matrigel (BD Biosciences) (1:10 in DMEM for trans-
fected B16-F10 cells and 1:50 in DMEM for transfected
MCF-7 cells) at 4°C for 36 hours and then incubated at
37°C for 2 hours. The filters were washed 4 times with
DMEM and were placed in the microchemotaxis cham-
bers. The cells were treated with 0.1% trypsin-EDTA, re-
suspended in DMEM media containing 10% FBS and then
washed with serum-free DMEM media. Cells (1 × 105)
were finally suspended in DMEM (200 μl) and placed in
the upper compartment of the chemotaxis chambers. Cul-
ture medium (300 μl) containing 20% FBS was placed in
the lower compartment of the chemotaxis chamber to
serve as a source of chemoattractants. After being incu-
bated in the cell culture incubator for 10 hours (for trans-
fected B16-F10 cells) or 24 hours (for transfected MCF-7
cells), the cells on the upper surface of the filter were com-
pletely wiped away with a cotton swab. The cells on the
lower surface of the filter were fixed in methanol, stained
with Liu's A and Liu's B reagents, and then counted under
a microscope. Cells invaded to the microchemotaxis
chambers were also counted. For each replicate, the
tumour cells in 10 randomly selected fields were deter-
mined, and the counts were averaged.
Animal metastasis experiment
C57BL/6 mice between 6–7 weeks old (National Labora-
tory Animal Center, Taipei, Taiwan) were housed in an
animal holding room under standard conditions (22°C;
50% humidity; 12-hours light/dark cycle). Each C57BL/6
mouse was injected with viable B16-EV cells or B16-anti-
CAS cells (5 × 104 cells in 50 μl DMEM/mouse) in the tail
vein. Each experimental group included 11 B16-EV cells-
injected mice and 11 B16-anti-CAS cells-injected mice,
and totally 66 mice were used in the experiment. Twenty-
five days after injection, the mice were sacrificed and
necropsied. The numbers of tumours in lungs were
counted by macrography and micrography. Mouse care
and experimental procedures were performed following
the guideline of the Animal Care Committee of Academia
Sinica, Taiwan.
Statistical analysis
All values are expressed as mean ± standard deviation
(SD). Statistical differences were analyzed by two-tailed
Student's t-test. The α-level of 0.05 was used to determine
statistical significance.
Results
Increased CAS expression is unable to enhance the 
proliferation of MCF-7 cancer cells
MCF-7 cells were separately transfected with pcDNA3.1
control vector (EV), pcDNA-CAS vector (CAS), and
pcDNA-anti-CAS vector (anti-CAS) to obtain MCF-EV,
MCF-CAS, and MCF-anti-CAS cells, respectively (Fig. 1a).
For reducing cellular CAS level, antisense DNA method is
better than such techniques as gene knockout or siRNA for
this study. Because CAS is essential for cell survival,
knockout of the CAS gene or extreme CAS reduction may
affect cell survival [22]. Also, CAS was identified in a study
of an antisense DNA fragment that is capable of causing
cell resistance to apoptosis induced by bacterial toxins
[17]; hence reduction of cellular CAS levels by antisense
DNA fragment against CAS is sufficient to obtain the cel-
lular effect of CAS reduction. We assayed the prolifera-
tions of MCF-EV, MCF-CAS, and MCF-anti-CAS cells to
study the effect of CAS expression on the proliferation of
MCF-7 cancer cells. CAS is a cellular apoptosis susceptibil-
ity protein, thus high CAS expression may be toxic to cells.
In the routine cell cultures, we have noted that the growth
of MCF-CAS cells was obviously slower than that of MCF-
EV and MCF-anti-CAS cells, probably due to the cytotox-
icity of CAS. CAS is essential for cell survival, and most
MCF-7 cells died after being transfected with the anti-CAS
vector (data not shown). However, the growth rate of the
established stable cell line, MCF-anti-CAS cells, was simi-
lar to the growth rate of the MCF-EV cells (Fig. 1b). On the
other hand, the results of cell proliferation assays showed
that the growth rate of MCF-CAS cells was indeed slower
than that of MCF-EV cells and MCF-anti-CAS cells (Fig.
1b). We speculate that the cytotoxicity of CAS might
account for the inhibition of cell proliferation of MCF-
CAS cells by CAS. Thus, flow cytometry analyses were per-
formed to study whether CAS overexpression induces
cytotoxicity of MCF-7 cells and reduces cell proliferation.
MCF-EV and MCF-CAS cells were cultured for 24 or 96
hours and FACS analyses based on DNA content were
used to determine the cell cycle distribution. The phase
distributions were 56.0% at G1, 22.4% at S, and 21.6% at
G2/M for MCF-EV cells cultured for 24 hours; 55.2% at
G1, 20.4% at S, and 24.4% at G2/M for MCF-CAS cells
cultured for 24 hours; 57.0% at G1, 16.2% at S, and
26.8% at G2/M for MCF-EV cells cultured for 96 hours;
58.2% at G1, 11.3% at S, and 30.5% at G2/M for MCF-
CAS cells cultured for 96 hours. The percentages of cells in
sub-G1 phase were 1.0% for MCF-EV cells cultured for 24
hours, 1.2% for MCF-CAS cells cultured for 24 hours,
2.0% for MCF-EV cells cultured for 96 hours, and 6.4% for
MCF-CAS cells cultured for 96 hours. The sub-G1 fraction
in a DNA histogram determined by flow cytometry is con-Page 4 of 12
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Increased CAS expression is unable to increase the proliferation of MCF-7 cellsFigure 1
Increased CAS expression is unable to increase the proliferation of MCF-7 cells. (a) Immunoblotting of CAS 
expression in MCF-EV, MCF-CAS, and MCF-anti-CAS cells. (b) The growth curves of MCF-EV, MCF-CAS, and MCF-anti-CAS 
cells. The graph represents the results of three independent assays. (c) Flow cytometry analyses showed increased CAS 
expression induced cytotoxicity of MCF-7 cells and decreased cell proliferation. Two experiments with two duplicates were 
performed and showed similar results; a representative result is shown here. Please see the text for detail.
Journal of Experimental & Clinical Cancer Research 2008, 27:15 http://www.jeccr.com/content/27/1/15sidered to be the apoptotic cells. The results showed that
CAS overexpression (i.e. MCF-CAS cells) increased the
percentage of sub-G1 fraction of cells (Fig. 1c). The results
also showed that CAS overexpression decreased the per-
centage of MCF-7 cells in S-phase (Fig. 1c). Thus, CAS
overexpression induces cytotoxicity of MCF-7 cells and
reduces cell proliferation.
CAS is located in cytoplasm vesicle near cell membrane 
and cell protrusion
Immunofluorescence observations with anti-CAS mono-
clonal antibodies showed punctual staining of CAS in
cytoplasm around perinuclear areas and areas near cell
membrane as well as in the cell protrusions of MCF-7 cells
and 293 cells (Fig. 2a). CAS binds strongly with importin-
α, a nuclear-transport receptor [23], thus CAS around
perinuclear areas may mainly associate with the importin-
α complex. The punctual staining of CAS in cytoplasm
areas near cell membrane and cell protrusion indicates
that CAS may be located in cytoplasm vesicles. We studied
the location of CAS by electron microscopy. Immunogold
electron microscopy analyses showed that CAS (12-nm
gold, arrows) was located in vesicle and mainly in the ves-
icle membrane (Fig. 2b).
CAS colocalizes with MMP-2
Our data show that CAS may be located in cytoplasm ves-
icles. Cytoplasm vesicle plays an important role in regulat-
ing cell exocytosis [24]. Thus, CAS may regulate the
secretion of tumor cells and hence regulates the invasion
and metastasis of cancer cells. MMP-2 plays an important
role in regulating tumor metastasis. Our double-stain
immunofluorescence studies showed that although not
all CAS was colocalized with MMP-2, there were indeed
many CAS colocalized with MMP-2 in MCF-7 and 293
cells (Fig. 3).
CAS regulates MMP-2 distribution
The effects of CAS expression on MMP-2 distribution were
studied by double-stain immunofluorescence. In MCF-EV
cells, colocalizations of MMP-2 with CAS were mainly
observed at cytoplasm areas near cell membrane, and only
some in cell protrusions (Fig. 4a). In MCF-CAS cells,
many MMP-2 was efficiently translocated to cell protru-
sions and was obviously colocalized with CAS (Fig. 4a). In
our observations, colocalizations of CAS with MMP-2 in
MCF-EV cells were only observed in one or two cells per
microscopic field. But in MCF-CAS cells, colocalizations
of CAS with MMP-2 were observed in most cells especially
Immunofluorescence show granular staining pattern of CAS in cytoplasm areas near cell membrane and cell protrusionsFigure 2
Immunofluorescence show granular staining pattern of CAS in cytoplasm areas near cell membrane and cell 
protrusions. (a) Immunofluorescence analyses with anti-CAS antibodies showed punctual staining of CAS in the cytoplasm 
areas near cell membrane and the cell protrusions of MCF-7 cells and 293 cells. The scale bar represents 20 μm. (b) Immuno-
gold electronmicroscopy analyses showed CAS (12-nm gold, arrows) was localized in vesicle and mainly in the vesicle mem-
brane in MCF-7 cells. N indicates nucleus. Original magnification: × 250,000.Page 6 of 12
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CAS was found to be colocalized with cytoplasmic vesicle
and MMP-2 (Fig. 4b).
CAS regulates MMP-2 secretion and invasion of cancer 
cells
MCF-EV, MCF-CAS, and MCF-anti-CAS cells were grown
to confluence and then cultured in media without serum
supplement for 36 hours. The conditioned media were
harvested and were subjected to immunoblotting with
anti-MMP-2 antibodies. The results showed that MMP-2
secretion from cells was enhanced by increased CAS
expression and was reduced by CAS reduction (Fig. 5a).
The effects of CAS expression on invasion of MCF-7 cancer
cells were assayed by matrigel-based invasion assays. The
results showed that increased CAS expression enhanced
the invasion of MCF-7 cells by 236.8% (P = 0.0024), and
reduced CAS expression inhibited the invasion of MCF-7
cells by 57.9% (P = 0.0098). The average numbers of the
invaded cells were 45.7 ± 4.1, 19.6 ± 6.5, and 8.2 ± 2.1
(cells/field) for MCF-CAS, MCF-EV, and MCF-anti-CAS
cells, respectively (Fig. 5b). The secretion of MMP-2 from
another tumor cell line, B16-F10 melanoma cells, was
also studied. B16-F10 cells were separately transfected
with the EV, CAS, and anti-CAS vectors to obtain B16-EV,
B16-CAS, and B16-anti-CAS cells, respectively (Fig. 5c).
The results of MMP-2 secretion assays also showed that
increased CAS expression enhanced MMP-2 secretion,
and reduced CAS expression decreased MMP-2 secretion
of B16-F10 melanoma cells (Fig. 5d). Matrigel-based inva-
sion assays showed that increased CAS expression
enhanced the invasion of B16-F10 cells by 249.2% (P =
0.0019), and reduced CAS expression inhibited the inva-
sion of B16-F10 cells by 75.7% (P = 0.0073). The average
numbers of the invaded cells were 89.5 ± 10.7, 35.9 ± 9.4,
and 8.7 ± 2.2 (cells/field) for B16-CAS, B16-EV, and B16-
anti-CAS cells, respectively (Fig. 5e). Thus, the results of
matrigel-based invasion assay indicate that CAS can regu-
late the invasion of cancer cells.
CAS regulates the metastasis of B16-F10 melanoma cells
Experimental animal tumour metastasis assays were done
to study the effect of CAS expression on the metastasis of
B16-F10 melanoma cells. B16-F10 cells are high meta-
static in C57BL/6 mice, thus we studied whether CAS
reduction can reduce the metastasis of B16-F10 cells in
CAS colocalizes with MMP-2Figure 3
CAS colocalizes with MMP-2. Immunofluorescence analyses with anti-CAS and anti-MMP-2 antibodies showed CAS was 
colocalized with MMP-2 in MCF-7 cells and 293 cells. Arrows indicate some of the colocalzations. The scale bar represents 20 
μm.Page 7 of 12
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CAS regulates MMP-2 translocationFigu  4
CAS regulates MMP-2 translocation. (a) Double-stain immunofluorescence analyses of MMP-2 and CAS distributions in 
MCF-EV, MCF-CAS, and MCF-anti-CAS cells. Please note the increased distribution of MMP-2 in the cell protrusions of MCF-
CAS cells. Arrows indicate some of the cell protrusions. The scale bar represents 20 μm. (b) Double-stain immunofluores-
cence showed CAS was colocalized with cytoplasmic vesicle and MMP-2 in MCF-CAS cells. Arrows indicate some of the colo-
calizations. The scale bar represents 30 μm.
Journal of Experimental & Clinical Cancer Research 2008, 27:15 http://www.jeccr.com/content/27/1/15C57BL/6 mice. Animal tumour metastasis experiments
showed that reduced CAS expression decreased the pul-
monary metastasis of B16-F10 cells by 56% in C57BL/6
mice (P = 0.0107). The average lung tumour numbers of
mice injected with B16-EV cells were 32.7 ± 6.5 tumours/
mouse (average tumour diameter 2.6 ± 1.8 mm) and were
14.3 ± 4.6 tumours/mouse (average tumour diameter 2.5
± 1.5 mm) for mice injected with B16-anti-CAS cells (Fig.
6). Eleven B16-EV cells-injected mice and six B16-anti-
CAS cells-injected mice passed away three weeks after
injection. Thus, anti-CAS transfection reduced the mortal-
ity of mice injected with B16-F10 cells; probably due to
anti-CAS transfection reduces the metastasis ability of
B16-F10 cells. The results of animal tumour metastasis
experiment indicate that CAS can regulate the metastasis
of cancers.
Discussion
CAS is regarded as a proliferation-associated protein that
associates with tumour proliferation as it associates with
microtubule and functions in the mitotic spindle check-
point [1-5,10]. But our data showed that CAS overexpres-
CAS regulates MMP-2 secretion and invasion of cancer cellsFigu  5
CAS regulates MMP-2 secretion and invasion of cancer cells. (a) CAS regulates MMP-2 secretion of MCF-7 cells. (b) 
Matrigel-based invasion assays of MCF-EV, MCF-CAS, and MCF-anti-CAS cells. Data represent the means of three independent 
experiments. (c) Immunoblotting of CAS expression in B16-EV, B16-CAS, and B16-anti-CAS cells. (d) CAS regulates MMP-2 
secretion of B16-F10 cells. (e) Matrigel-based invasion assays of B16-CAS, B16-EV, and B16-anti-CAS cells. The upper is a rep-
resentative photograph of the invaded cells. Data represent the means of three independent experiments.Page 9 of 12
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did reduce the proliferation of MCF-7 cells. The involve-
ment of CAS in proliferation of cancer cells is supported
by a study showing that reduction of cellular CAS protein
by transfection of antisense cDNA against CAS in HeLa
cells perturbed progression from G2 (retards transition
from G2) to G1 in the cell cycle [25]. CAS may be neces-
sary for M phase mitotic spindle checkpoint in cell cycle
progression, but it is quite impossible that tumour cells
highly expressing CAS can increase tumour proliferation.
The key step that determines the rate limiting for cell pro-
liferation is mainly at the G1-S phase of cell cycle rather
than at the mitotic phase [26,27]. Also, CAS is associated
with mitotic spindle and regulates the mitotic spindle
checkpoint, thus CAS may halt the progression of mitosis
until the cells are truly ready to divide. p53 protein also
plays a role in activating cell cycle checkpoints, and activa-
tion of p53 can stop cell cycle progression at the cell cycle
checkpoints [28,29]. The involvement of CAS in prolifer-
ation of cancer cells is also supported by a pathological
study showing that the expression of the Ki67 prolifera-
tion marker in lymphomas was significantly positive cor-
related with CAS [3]; however this study also reported that
a significant fraction of CAS-positive normal and malig-
nant lymphocytes were also found to be Ki-67 negative
[3]. In tumours, various oncogenes are activated and vari-
ous anti-oncogenes are inactivated [30,31], the activated
oncogenes and the inactivated anti-oncogenes may stimu-
late the proliferation of tumours that highly expressing
CAS. Thus, positive correlation between CAS and Ki67
expression in tumours is not sufficient to make a conclu-
sion that CAS is related with tumour proliferation. As an
apoptosis susceptibility protein, highly expression of CAS
can cause the cells susceptible to apoptosis. Our flow
cytometry cell cycle study showed that CAS highly
expressed in cancer cells can induce cytotoxicity of cells
and decreases the proliferation of the cells (Fig. 1).
Formation of cell polarity can stimulate cell-cell adhesion,
inhibit tumour migration, and decrease cell proliferation
[32]. We have reported that CAS stimulated the polarity of
HT-29 cancer cells and thus inhibited the migration of
HT-29 cells [11,33]. These results are contradictory to our
present report that CAS enhances the metastasis of cancer
cells. HT-29 cell line is a special cell line as it is easy to
form polarity under in vitro cell culture [34]. In another
study, we have observed that CAS was unable to stimulate
the polarity of other cancer cell lines including B16-F10,
MCF-7, Colon 205, Hep G2, and SK-Hep-1 cancer cells
(data not shown). CAS was also unable to increase the
proliferation of these cells (data not shown). Thus, the
ability of CAS on polarity formation and migration inhi-
bition seems to be a special phenomenon that happened
restrictively in HT-29 cell line and the increase of invasion
and metastasis should be the correct role of CAS on
tumour development.
Although MMPs were previously believed to be synthe-
sized and rapidly secreted, later experiment shows that
MMPs are stored in the secretory vesicles in cells and are
rapidly secreted in response to angiogentic stimuli [35].
Thus, regulation of the secretion of ECM-degradation pro-
teinases from tumour cells may also plays an important
role in regulating tumour metastasis. Our data showed
that CAS was localized in vesicle and CAS overexpression
enhanced the secretion of MMP-2 and enhanced the inva-
sion and metastasis of tumour cells. Pathological studies
also showed that CAS was highly expressed in the meta-
static tumours and the expression of CAS was correlated
positively with high cancer stage, high cancer grade, and
worse outcome of the cancer patients. Taken together,
CAS may play an important role in regulating tumour
metastasis and CAS plus ECM-degradation proteinases
Animal tumor metastasis experiments show CAS regulates the etastasis of B16-F10 melanoma cellsFigur  6
Animal tumor metastasis experiments show CAS 
regulates the metastasis of B16-F10 melanoma cells. 
Eleven B16-EV cells-injected mice and six B16-anti-CAS cells-
injected mice passed away three weeks after injection thus 
were excluded from the statistics. Six mice (three B16-EV 
cells-injected mice and three B16-anti-CAS cells-injected 
mice) didn't grow tumour in lungs and thus were also 
excluded from the statistics. The results showed that 
reduced CAS expression inhibited the pulmonary tumour 
metastasis of B16-F10 melanoma cells in C57BL/6 mice.Page 10 of 12
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tumour metastasis.
Conclusion
CAS regulates the invasion but not the proliferation of
cancer cells. CAS plus ECM-degradation proteinases may
be used as the markers for predicting the advance of
tumour metastasis.
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